US EditionFour-Biomarker Blood Panel Enhances the Detection of Pancreatic Ductal Adenocarcinoma
A blood test measuring four biomarkers detected pancreatic cancer with 91.9% accuracy, improving early-stage detection though gains were not statistically significant.
4 Articles
4 Articles
Four-biomarker blood panel enhances the detection of pancreatic ductal adenocarcinoma
A four-biomarker blood panel of aminopeptidase N (ANPEP), polymeric immunoglobulin receptor (PIGR), CA19-9, and thrombospondin-2 (THBS2) enhanced the detection of pancreatic ductal adenocarcinoma (PDAC) compared to measuring CA19-9 levels alone.
Investigational blood biomarker panel may improve detection of pancreatic cancer
A four-biomarker blood panel of aminopeptidase N (ANPEP), polymeric immunoglobulin receptor (PIGR), CA19-9, and thrombospondin-2 (THBS2) enhanced the detection of pancreatic ductal adenocarcinoma (PDAC) compared to measuring CA19-9 levels alone, according to a study published in Clinical Cancer Research.
[Life is tough, ears are tough, compiled by the Prefectural Medical Association] (1376) Pancreatic cancer is said to be the "most difficult cancer to cure." The pancreas is an organ located behind the stomach, and is known as the "silent organ" because symptoms are difficult to detect. This means that diagnosis is often delayed, and by the time it is discovered, it is often already so advanced that surgery is no longer possible.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
